Puma Biotechnology (PBYI) Non Operating Income (2011 - 2026)
Puma Biotechnology (PBYI) reported Non Operating Income of $401000.0 for Q1 2026, up 11.7% on a YoY basis from $359000.0 in Q1 2025, and up 116.7% quarter-over-quarter from -$2.4 million in Q4 2025.
Puma Biotechnology (PBYI) Non Operating Income (2011 - 2026) Analysis & Trends
Puma Biotechnology has reported Non Operating Income for 16 years, with the latest figure at $401000.0 in Q1 2026.
- For the quarter ending Q1 2026, Non Operating Income rose 11.7% year-over-year to $401000.0; the trailing twelve-month figure through Mar 2026 stood at -$1.9 million (down 269.91% YoY), and the FY2025 full-year result was -$1.5 million, down 275.99% from the prior year.
- Non Operating Income for Q1 2026 stood at $401000.0, up from -$2.4 million in the prior quarter.
- The five-year high for Non Operating Income was $410000.0 in Q2 2025, with the low at -$23.4 million in Q4 2022.
- Historically, Non Operating Income has averaged -$2.3 million across 5 years, with a median of $62000.0 in 2022.
- The largest YoY upside for Non Operating Income was 368.92% in 2024 against a maximum downside of 5366.67% in 2024.
- Puma Biotechnology's Non Operating Income stood at -$23.4 million in 2022, then surged by 56.98% to -$10.1 million in 2023, then surged by 102.66% to $268000.0 in 2024, then plunged by 995.9% to -$2.4 million in 2025, then jumped by 116.7% to $401000.0 in 2026.
- The last three Non Operating Income figures came in at $401000.0 (Q1 2026), -$2.4 million (Q4 2025), and -$330000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Op. Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | 5.75 Mn |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | - |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | 444,000.00 |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | - |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | 9.35 Mn |
| 10 | Puma Biotechnology | 384.39 Mn | 282.84 Mn | 34.39 Mn | 401,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 401,000.00 |
| Dec 31, 2025 | -2.40 Mn |
| Sep 30, 2025 | -330,000.00 |
| Jun 30, 2025 | 410,000.00 |
| Mar 31, 2025 | 359,000.00 |
| Dec 31, 2024 | 268,000.00 |
| Sep 30, 2024 | 347,000.00 |
| Jun 30, 2024 | 156,000.00 |
| Mar 31, 2024 | -2.30 Mn |
| Dec 31, 2023 | -10.08 Mn |
| Sep 30, 2023 | 74,000.00 |
| Jun 30, 2023 | 86,000.00 |
| Mar 31, 2023 | -42,000.00 |
| Dec 31, 2022 | -23.44 Mn |
| Sep 30, 2022 | -2.69 Mn |
| Jun 30, 2022 | 62,000.00 |
| Mar 31, 2022 | 50,000.00 |
| Dec 31, 2021 | -30.27 Mn |
| Sep 30, 2021 | -35.68 Mn |
| Jun 30, 2021 | 11.57 Mn |